Catalyst Dossier · compiled by CeliA 🧫
CNS Pharmaceuticals, Inc. (CNSP)
Pharmaceutical Preparations · market cap $8M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
CNS Pharmaceuticals (CNSP) is a micro-cap clinical-stage biotech with 4 employees and an ~$8M market cap, focused entirely on Berubicin, an anthracycline derivative in Phase 2 for recurrent or newly diagnosed Glioblastoma Multiforme (GBM) in adults. The company holds approximately $3.0M in cash against a reported runway of under two months, creating acute near-term financing risk. No upcoming catalysts are calendared and no recent data readouts have been disclosed.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Berubicin | Phase 2 | Glioblastoma Multiforme, Adult |
Price & technical context
3-month
-26.6%
6-month
-30.1%
12-month
-90.7%
52-wk range
$5.09–$85.50
vs 50-day MA
-13.3%
vs 200-day MA
-36.2%
Realized vol
138.7%
Max drawdown
-100.0%
Daily closes through 2026-01-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CNSP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.